A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC

Summary

This is a Phase II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With unresectable Hepatocellular Carcinoma. This study aims to evaluate the safety and efficacy of SHR-1210 combination with Apatinib as a preoperative treatment of unresectable HCC.

Timeline

Start

2019-01-30

Primary completion

2020-01-30

Completion

2021-01-30

Drugs

Indications